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Abstract
Glioblastoma multiforme (GBM) is the most common adult primary brain tumor and is comprised of
a heterogeneous population of cells. It is unclear which cells within the tumor mass are responsible
for tumor initiation and maintenance. In this study, we report that brain tumor stem cells can be
identified from adult GBMs. These tumor stem cells form neurospheres, possess the capacity for
self-renewal, express genes associated with neural stem cells (NSCs), generate daughter cells of
different phenotypes from one mother cell, and differentiate into the phenotypically diverse
populations of cells similar to those present in the initial GBM. Having a distinguishing feature from
normal NSCs, these tumor stem cells can reform spheres even after the induction of differentiation.
Furthermore, only these tumor stem cells were able to form tumors and generate both neurons and
glial cells after in vivo implantation into nude mice. The identification of tumor stem cells within
adult GBM may represent a major step forward in understanding the origin and maintenance of
GBM and lead to the identification and testing of new therapeutic targets.

Keywords: cancer stem cells, adult brain tumors, glioblastoma multiforme, glioblastoma spheres, in
vivo implantation
Introduction
Glioblastoma multiforme (GBM) is typically comprised of morphologically diverse cells within the
tumor mass. Despite current advances in therapy, the morbidity and mortality of GBM remain very
high (Surawicz et al., 1998). This is due, at least in part, to the focus of most treatments on the bulk
of the tumor. However, the diverse cells within GBM may play different roles in tumorogenesis.
There is increasing evidence that cancers might contain and arise from stem cells. Studies on
leukemia and breast carcinoma have demonstrated that a small group of cells within the tumor mass
is responsible for tumor formation and maintenance. This subpopulation of stem-like cells plays an
important role in the tumorogenic process (Lapidot et al., 1994; Larochelle et al., 1996; Bonnet and
Dick, 1997; Al-Hajj et al., 2003; Dick, 2003). GBMs contain cells that express neural markers as well
as cells that express glial markers, indicating that there may be multipotent neural stem cell-like cells
(Ignatova et al., 2002; Katsetos et al., 2002). Such mixed glioblastomas may develop from neural
stem cells (NSCs) or from differentiated cell types that acquired multipotential stem cell-like
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properties by either reprogramming or de-differentiating in response to oncogenic mutation (Kondo
and Raff, 2000; Bachoo et al., 2002; Zhu and Parada, 2002). This plasticity of central nervous system
(CNS) cells has already been reported as normal oligodendrocyte precursor cells can be induced to
acquire stem cell-like properties (Kondo and Raff, 2000; Belachew et al., 2003; Nunes et al., 2003).
Very recent studies show that pediatric brain tumors and a rat glioma cell line contain cancer stem
cells that may be important for the malignancy (Hemmati et al., 2003; Singh et al., 2003; Kondo et
al., 2004). Here, we demonstrate that human adult GBMs contain a subpopulation of cells that can
form neurospheres in defined stem cell medium with growth factors. The spheres share many
characteristics of stem cells, including self-renewal ability and multipotent differentiation, which can
produce daughter cells of all phenotypes present in the GBM. Furthermore, we show that these
spheres are different from normal neurospheres, being able to reform new spheres after the
induction of differentiation. More importantly, after in vivo implantation only the isolated tumor
stem cells were able to form tumors that contained both neurons and glial cells. Our findings suggest
that a subpopulation of cells exist within adult GBM, which may represent a general source of cancer
stem cells in adult brain tumor and need to be targeted for more effective and specific cancer
therapy.

Results
Primary cultures of GBM contain 'neurospheres' forming cells that can self-renew
Phenotypically diverse cell populations exist in a tumor mass of GBM. To determine whether there is
a population of cells with distinct proliferative ability characteristic of stem cells distinguishable from
other cells, we studied four GBM primary cultures, GBM1–4, grown from frozen stocks of the first
passage of tumor cells, and two freshly resected GBM cultures, GBM5 and 6, directly cultured
without freezing. The six GBM primary cultures were grown as monolayers attached at the bottom
of flasks in a medium containing FBS. We switched the GBM cells into culture conditions known to
be permissive for stem cell proliferation, established previously for isolation of NSC as neurospheres
(Reynolds and Weiss, 1992; Kabos et al., 2002). Neurosphere-like colonies appeared in all six GBM
cultures after 1 week and reached 100–200 each after 2 weeks. We have denoted these colonies as
glioblastoma spheres (Figure 1a). These glioblastoma spheres were harvested and subjected to
subsphere-forming assay by limiting dilution (Kabos et al., 2002). Subspheres formed in the wells
seeded with individual sphere cells with efficiency between 3 and 5% for the six GBMs (Figure 1b
and c). However, sphere formation was not evident in any wells seeded with monolayer cells. When
compared with normal human NSCs that were also grown from frozen stocks with the same passage
number, there were <1% cells with subsphere-forming ability (Figure 1c). This observation indicates
that the glioblastoma spheres have a self-renewing ability. To confirm this ability, the subspheres
were harvested and a second round subsphere-forming assay was performed as above. Again, we
found that individual cells formed further spheres with an efficiency similar to that of the previous
assay (Figure 1c).
One mother-cell-derived glioblastoma spheres express NSC markers as well as lineage markers
The self-renewal capability of glioblastoma spheres indicates that sphere cells isolated from GBM
primary cultures share this property with the NSC. We next tested whether the glioblastoma spheres
2
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could express genes characteristic of NSC. Spheres derived from a single mother cell and isolated by
subsphere-forming assay were dissociated and expanded. Two NSC markers were chosen to
characterize the expanded spheres: CD133, a cell surface marker of normal human NSCs (Miraglia et
al., 1997; Uchida et al., 2000), and nestin, a cytoskeletal protein associated with NSCs and progenitor
cells in the developing CNS (Lendahl et al., 1990). For all six GBMs studied, daughter spheres derived
from one mother cell were positive for both CD133 and nestin (Figure 2a). However, <0.5% cells of
the non-sphere-forming tumor cells in the monolayer culture stained positive for CD133 and nestin.
Some cells within tumor spheres were also found to be positive for lineage markers β-tubulinIII and
myelin/oligodendrocyte, but no GFAP staining was detected within spheres (Figure 2a), although a
few cells were positive for GFAP in dissociated sphere cells. The cells in non-sphere-forming
monolayer cultures predominantly expressed the three lineage markers of CNS, β-tubulinIII (30–
50%), GFAP (10–25%), and myelin/oligodendrocyte (20–40%). The pattern was clearly different from
that of the glioblastoma sphere staining, it was 5–15% for β-tubulinIII, 1–5% for GFAP, and 10–20%
for myelin/oligodendrocyte. An example is shown in Figure 2b and c. The observed phenotypic
variation of stained cells within spheres from one mother cell indicates that the mother cell has the
potential to produce the terminal cell types specific to the tumor tissue.
One mother-cell-derived glioblastoma sphere is multipotent
To test whether glioblastoma spheres derived from one mother cell have multipotent ability and
produce progenies of different lineages, the spheres were subjected to a differentiation assay.
Single-cell suspensions of glioblastoma spheres were differentiated and stained for various lineage
markers. The results demonstrate that cells differentiated from tumor sphere were positive for βtubulinIII, GFAP, and myelin/oligodendrocyte. Furthermore, a few cells were nestin or CD133
positive (Figure 3a). For all GBM samples, the staining pattern of the differentiated progeny was
similar in profile to that of primary cultured tumor cells from which the glioblastoma spheres had
originally been isolated (Figure 3b and c). However, the phenotype pattern was different from that
of normal human NSC, which was also grown from frozen stock, and cultured for the same period of
time as that of glioblastoma spheres. As shown in Figure 3d, the differentiated progeny of normal
NSCs was characterized with 50–60% GFAP-positive cells, 20–30% β-tubulinIII-positive cells,
myelin/oligodendrocyte-stained cells accounting for 10%, and less than 5% cells positive for CD133
or nestin, respectively. In contrast, glioblastoma spheres predominantly differentiated into βtubulinIII (80%) and myelin/oligodendrocyte (25%)-positive cells that recapitulated the parental
tumor phenotype (Figure 3b and c). Furthermore, we found that there were approximately 5% βtubulinIII and GFAP double-positive-stained cells only in glioblastoma sphere-differentiated
progenies. These results reveal that glioblastoma spheres are multipotent for the three neural cell
types, but different from normal human neurospheres regarding the phenotype of their progenies.
The mRNA transcriptional levels are different between glioblastoma spheres and their differentiated
progeny
To better define the multipotent ability, a single glioblastoma sphere derived from one mother cell
was scaled up for semiquantitative RT–PCR to assess the mRNA levels of lineage marker and NSC
genes. Half of the spheres were directly subjected to RNA extraction. The rest was differentiated first
for 2 weeks prior to RNA extraction. As shown in Figure 4a as a representative, nestin mRNA was
only detected in the glioblastoma sphere and not in the differentiated progeny. Conversely, the PCR
3
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product of astrocyte marker GFAP was amplified in the differentiated progeny but not in the sphere.
Transcripts of neuronal and oligodendrocyte-specific genes were elevated in the differentiated
progenies. These results are consistent with the above findings that glioblastoma sphere derived
from one mother cell was able to generate multiple-lineage daughter cells.
Glioblastoma spheres are different from normal neurospheres in their ability to regain or maintain
NSC features after differentiation
The above results demonstrate that glioblastoma spheres possess a phenotype different from that
of normal human neurospheres upon differentiation (Figure 3c and d). To further determine that
glioblastoma spheres are cancer stem cells and not derived from contaminating normal NSC, we
conducted a differentiation experiment for both glioblastoma spheres and normal human
neurospheres by dissociating individual spheres into a single-cell suspension and subjecting the cells
to differentiation conditions. After 2 weeks of differentiation, all cells were attached and growing as
a monolayer. Cells were then switched into NSC growth medium. New spheres started to form in the
GBM-differentiated monolayers after 1 week. No spheres were observed in the normal human
neurosphere-differentiated monolayer even after 4 weeks. The newly formed glioblastoma spheres
stained positive for nestin and CD133 (Figure 4b). We also karyotyped the glioblastoma sphere cells
and identified chromosome loss, gain, and translocation events. Taken together, both cellular
analysis and genetic data support our hypothesis that glioblastoma spheres isolated from primary
GBM cultures are not normal NSCs migrated into the tumor mass. Rather, these glioblastoma
spheres possess abnormal characteristics including enhanced self-renewal and altered
differentiation abilites, which may be responsible for maintaining the tumor stem cell pool and also
for generating the differentiated progeny.
Glioblastoma spheres represent the tumor stem cells and are capable of forming tumors in vivo
To address whether glioblastoma spheres and non-sphere-forming monolayer cells differ in their
abilities to form tumor in vivo, we implanted the isolated glioblastoma spheres or non-sphereforming monolayer cells into the brain of nude mice. There was no tumor detected 6 weeks after 50
000 cells per mouse implantation of non-sphere-forming monolayer cells (n=6; Figure 5c). However,
all the mice developed brain tumors after the same number of glioblastoma sphere cell implantation
(n=6) (Figure 5a and c). We next increased the non-sphere-forming monolayer cells to 250 000 and
decreased the glioblastoma sphere cells to 5000 per mouse for the intracranial implantation. After 6
weeks, there was still no tumor detected in the non-sphere-forming monolayer cell-implanted mice
(n=6), but brain tumors were detected in all mice (n=6) implanted with glioblastoma sphere cells,
although the tumor size was smaller than that of the above (data not shown).
The tumors, which developed in mice brains after implantation of human glioblastoma spheres,
could be stained by human-specific antibodies against nestin (Figure 5d and e) and CD133 (Figure
5g–i), the NSC-related markers. Also, the tumor cells were stained positive for anti-GFAP, which was
not stained in the glioblastoma spheres in vitro (Figure 6a–c), anti-myelin/oligodendrocyte (Figure
6d–f), and anti-β-tubulinIII (Figure 6g–i), suggesting that the implanted glioblastoma spheres can
generate both glial cells and neurons in vivo. Thus, the malignance of the human adult GBM
apparently depends on the insolated glioblastoma spheres, the cancer stem cells.
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Discussion
The application of principles used for studying the NSCs to tumor biology indicates a link between
normal neurogenesis and brain tumorigenesis (Holland et al., 1998; 2000; Holland, 2001; Kabos et
al., 2002; Ehtesham et al., 2004). NSCs have the ability to generate three cell lineages: neuron,
astrocyte, and oligodendrocyte. Human adult GBM also contains all the three cell types within the
tumor mass. Until now, there has been no convincing evidence to show which cell type in GBM is the
root for tumor growth. Is there a stem cell population present within the tumor that is responsible
for the tumor growth and maintenance in GBM? Our data at least partially answered this question.
Currently, there is increasing evidence that some malignant tumors, both soluble and solid, contain
cancer stem cells that are responsible for the initiation and growth of malignancy (Lapidot et al.,
1994; Larochelle et al., 1996; Bonnet and Dick, 1997; Al-Hajj et al., 2003; Dick, 2003). Cancer stem
cells are potentially important because it is likely that the stem cell population within tumor mass
plays a key role for the recurrences that occur after current treatments. Thus, it is critical for cancer
therapy that treatments must target and eliminate this special population of cancer cells.
Consequently, the need to identify and study cancer stem cells becomes significant.
Our data indicate that human adult GBMs contain a subpopulation of cells that can self-renew and
differentiate into mature cell types, recapitulating the diverse complexity of primary GBMs. Several
lines of evidence support that we have isolated cancer stem cells from adult human GBMs: (1) the
isolated cells only account for a small fraction in tumor mass, form spheres that are morphologically
indistinguishable from normal neurospheres, and express known NSC markers; (2) the cells can selfrenew and proliferate to generate subspheres and different progenies; (3) the isolated single mother
cell can differentiate into multi-lineage progenies; (4) spheres derived from a single mother cell
possess a different phenotype compared with normal NSCs upon differentiation, can reform spheres
after the induction of differentiation, and display genetic aberrations commonly found in brain
tumor cells; (5) the isolated neurosphere-forming cells can produce brain tumors in nude mice,
whereas the non-sphere-forming monolayer cells do not.
In addition to providing further evidence for the existence of cancer stem cell in solid tumor, as the
presence of stem-like precursors in adult human glioblastomas has been independently reported
after our work was completed (Galli et al., 2004), our finding that cancer stem cells can reform new
spheres after the induction of differentiation has an important implication. It may, for example,
provide a basic strategy for identifying cancer stem cells from normal NSC. Although flow cytometric
isolation of subpopulations of cells from tumors has been used (Al-Hajj et al., 2003; Singh et al.,
2003; Kondo et al., 2004), there is no appropriate marker for isolating cancer stem cells, especially
for distinguishing cancer stem cells from NSCs. It is a fundamental step to identify and isolate cancer
stem cells, so that elucidating the pathways that account for tumorigenic potential and developing
effective and specific anticancer strategy may be realized. We found that glioblastoma spheres
derived from a single mother cell can differentiate into the three CNS cell lineages and recapitulate
the phenotypically complex property of the parental tumor. These data suggest that the presence of
varied cell types within the tumor is not simply a consequence of different types of cells growing
together to form tumor mass, but rather is an intrinsic property of cancer stem cells. The isolated
brain tumor stem cells, not only giving rise to further stem cells but also to a diverse population of
other phenotypes, may serve as a useful object for understanding the fundamental similarities and
differences between normal neurogenesis and tumorigenesis in CNS.
5
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An interesting implication arises from the ability of one glioblastoma cell to generate neurons as well
as astrocytes and oligodendrocytes. These cells were isolated from adults, suggesting that there are
two possibilities. On the one hand, these might be converted from normal NSC by oncogenic
stimulation. They were stem cells before acquiring the tumorigenic property. On the other hand,
these cells might be somehow either reprogrammed, or de-differentiated from a more
differentiated cell type in response to some signal transduction cascades (Kondo and Raff, 2000;
Bachoo et al., 2002; Zhu and Parada, 2002). Studying the molecular basis involved in the oncogenic
conversion of stem cells or the conversion from more differentiated cells into a stem cell-like
phenotype might shed light on the biology of both NSCs and cancer cells.
In conclusion, the present study highlights the importance of cancer stem cells in brain tumor
research and suggests a basic strategy to identify brain cancer stem cells from normal NSCs. The
study also indicates that the cancer stem cell of adult brain tumor may serve as a tool for studying
the basic biology of adult stem cells.

Materials and methods
Culture of primary glioblastoma cells and spheres
Tumor specimens were obtained within half an hour of surgical resection from six adult GBM
patients, as approved by the Institutional Review Boards at the Cedars-Sinai Medical Center. Tumor
tissue was washed, minced, and enzymatically dissociated (Reynolds and Weiss, 1992). Tumor cells
were resuspended in DMEM/F12 medium containing 10% fetal bovine serum (FBS) as growth
medium and plated at a density of 2 106 live cells per 75 cm2 flask. The cells attached and grew as a
monolayer in flasks. The frozen stock tumor cells, which were also subjected to the same procedure
as above and cryopreserved from monolayer cultures, were recovered into the growth medium. All
the six monolayer-growing adult glioblastoma cells were switched into a defined serum-free NSC
medium (Reynolds and Weiss, 1992) containing 20 ng/ml of basic fibroblast growth factor (bFGF,
Peprotech, Rocky Hill, NJ, USA), 20 ng/ml of epidermal growth factor (EGF, Peprotech) and 20 ng/ml
leukemia inhibitory factor (LIF, Chemicon).
Subsphere-forming assay
After primary spheres formed and reached 100–200 cells each in the monolayer culture, the sphere
cells were harvested, dissociated into single cells and plated into a 96-well plate for the subsphereforming assay by limiting dilution as described previously (Kabos et al., 2002). In brief, the cells in
single-cell suspension were diluted and plated at 1–2 cells/well. In parallel, the cell monolayer
remaining in the flasks after harvesting of the spheres was also plated. Cells were fed by changing
half of the medium every 2 days. After plating, the cells were observed and only wells containing a
single cell were considered. The wells were scored for sphere formation after 14 days.
Differentiation assay of spheres derived from one mother cell
Glioblastoma sphere derived from one mother cell in the subsphere-forming assay was trypsinized
into single-cell suspension and seeded into chamber slides (Lab-TekII, Nalge Nunc International) for
differentiation assay. The cells were grown in medium devoid of growth factors but permissive for
6
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differentiation for 14 days, and processed for immunocytochemistry (Kabos et al., 2002). For the
new sphere-reforming assay, the cells were switched back into NSC culture medium containing
growth factors after differentiation process.
Immunocytochemistry staining
To examine the expression of NSC markers and lineage markers, immunostaining was performed as
described previously (Kabos et al., 2002). For staining the primary cultured tumor cells and
differentiated glioblastoma sphere or normal neurosphere, the cells growing in precoated chamber
slides were fixed with 2% paraformaldehyde for 15 min at room temperature, treated with 10%
donkey serum, and then stained with the following antibodies: anti-CD133/1 (mouse monoclonal
IgG1; 1 : 10; Milteny Biotec), anti-nestin (mouse monoclonal IgG1; 1 : 200; Chemicon), anti-βtubulinIII (mouse monoclonal IgG1; 1 : 200; Chemicon), anti-GFAP (rabbit polyclonal; 1 : 1000;
Chemicon), and anti-myelin/oligodendrocyte (mouse monoclonal; 1 : 1000; Chemicon). The primary
antibodies were detected with Tex-Red or FITC-conjugated donkey anti-mouse IgG and FITCconjugated donkey anti-rabbit IgG (1 : 200; Jackson ImmunoRescearch). The cells were
counterstained with 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories) to identify all nuclei.
For immunostaining of glioblastoma spheres, the spheres or dissociated sphere cells were freely
floated in 'U'-bottom wells of a 96-well plate during the staining process. Then, the cells were
resuspended into the mounting medium containing DAPI and mounted on microslides.
Quantification of cells positive for a specific marker was carried out by counting all the stained cells
within 20 randomly selected microscope fields per specimen, and the percentage was calculated
based on the total number of nuclei counted.
RNA extraction and RT–PCR assay
Glioblastoma spheres derived from a single mother cell were expanded and differentiated as
outlined previously. Spheres and differentiated progeny were respectively subjected to total RNA
extraction with RNeasy kit (GIAGEN) and reverse transcripted by using a Bioscript kit (Bioline) and
Olig(dT)12–18 primer (Invitrogen). The PCR was carried out in a 20 l reaction mixture that contained
1 l cDNA as template, specific oligonucleotide primer pairs (Table 1), and Accuzyme (Bioline). Each
specific gene was concurrently amplified with internal control -actin in the same reaction tube. The
final primer concentrations were 400 and 200 nm for specific gene and -actin, respectively. Cycle
parameters for nestin, β-tubulinIII, GFAP, myelin-associated oligodendrocyte basic protein (MOBP),
and -actin amplification were 30 s at 94°C, 30 s at 61°C, and 60 s at 72°C for 25 cycles. The amplified
products were identified by agarose gel electrophoresis and ethidium bromide staining.
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Spectral karyotype analysis of glioblastoma sphere cells
The spheres were cultured and dissociated as described above. The cultured cells were harvested
within 5 days with Colemid (Invitrogen) for 2–3 h, KCL treated, and fixed with methanol : acetic acid
(3 : 1). The spectral karyotype analysis was performed on fixed metaphase cells according to the
manufacturer's instruction (ACI, Carlsbad, CA, USA). Spectral images were acquired and analysed.
Implantation into nude mice
Athymic nude mice (nu/nu; 6–8 weeks old; Charles River Laboratories, Wilmington, MA, USA) were
anesthetized with i.p. ketamine and xylazine, and stereotactically implanted with either isolated
glioblastoma sphere cells (5000; 50 000 per mouse) or non-sphere-forming monolayer cells (50 000;
250 000 per mouse) in 2.5 l of 1.2% methylcellulose/PBS in the right striatum. The experiment was
repeated once with identical situations. The implanted mice were killed after 6 weeks by intracordic
perfusion–fixation with 4% paraformaldehyde and examined for tumors on the brain sections as
described below. All of the animals used were experimented in strict accordance with the
Institutional Animal Care and Use Committee guidelines in force at the Cedars-Sinai Medical Center.
Hematoxylin–eosin and immunohistochemistry staining of brain sections
The tumor-cell-implanted mice brains were postfixed after the perfusion–fixation with 4%
paraformaldehyde, and cut with a vibratome into 40 m coral sections. For hematoxylin–eosin
staining, brain sections were mounted on slide and stained with Harris hematoxylin for 2 min first,
and then counterstained with alcoholic eosin. To characterize the brain tissue by
immunohistochemistry, free-floating sections were treated with 10% donkey serum (sigma) for 30
min at room temperature and then stained with primary antibodies for human-specific anti-nestin
(mouse monoclonal IgG1; 1 : 200; Chemicon), anti-CD133/1 (mouse monoclonal IgG1; 1 : 10; Milteny
Biotec), and both human and mice reactive anti-β-tubulinIII (mouse monoclonal IgG1; 1 : 200;
Chemicon), anti-GFAP (rabbit polyclonal; 1 : 1000; Chemicon), and anti-myelin/oligodendrocyte
(mouse monoclonal; 1 : 1000; Chemicon) antibodies. The primary antibodies were detected as
described above.
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Figure Legends
Figure 1: Primary cultures of adult GBM form glioblastoma spheres that can self-renew. (a) Primary
neurosphere-like colony, glioblastoma sphere, developing from monolayer tumor cells. Scale bar=50
m. (b) Subsphere derived from a single cell of primary sphere. Scale bar=50 µm. (c) Two rounds of
subsphere-forming assay for glioblastoma spheres and normal human neurospheres. The data
shown represent means and standard deviations of triplicate experiments
Figure 2: Single-mother-cell-derived glioblastoma spheres express NSC markers as well as lineage
markers, but with different staining profile from non-sphere tumor cells. (a) Glioblastoma spheres
derived from a single mother cell were stained by NSC markers CD133 (red) and Nestin (green).
Lineage markers for neuron, β-tubulinIII (red) and oligodendrocyte, myelin/oligodendrocyte (green)
were stained, but staining for the astrocyte marker, GFAP, was not observed in the glioblastoma
sphere. Cells were located by counterstaining with DAPI (blue). Scale bar=50 µm. (b) Dissociated
glioblastoma sphere cells show immunostaining for various markers. (c) Non-sphere monolayer cells
show different staining profile from sphere cells. The data shown in (b) and (c) represent means and
standard deviations of triplicate experiments
Figure 3: Glioblastoma sphere-differentiated progenies show a phenotype similar to the parental
tumor, but different from that of normal human neurospheres. (a) Differentiated progenies of
glioblastoma spheres were stained for the NSC markers, CD133 (red) and Nestin (green). The cells
were also stained for lineage-specific markers of neuron (red), astrocyte (green) and
oligodendrocyte (green). Scale bar=50 µm. (b) The phenotype of primary cultured parental tumor
cells. (c) The phenotype of differentiated progenies from glioblastoma spheres. (d) The phenotype of
differentiated progenies from human normal neurospheres. The data shown in (b–d) represent
means and standard deviations of triplicate experiments
Figure 4: Semiquantitative RT–PCR and new spheres reformed from differentiated cells. (a)
Semiquantitative RT–PCR showing mRNA transcription levels within undifferentiated glioblastoma
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sphere and differentiated monolayer cells. Both were derived from the same single mother cell. Lane
1: 1 kb ladder (L); lanes 2 and 6: NSC marker gene, nestin (N); lanes 3 and 7: neuron marker gene, βtubulin (T); lanes 4 and 8: oligodendrocyte marker gene, MOBP, myelin-associated oligodendrocyte
basic protein (M); lanes 5 and 9: astrocyte marker gene, GFAP, glial fibrillary acidic protein (G). A
representative of three experiments is shown. (b) New spheres developed again after the previous
glioblastoma spheres differentiation process. The spheres were stained for CD133 (upper panel, red)
and Nestin (lower panel, green). Cells were located by counterstaining with DAPI (blue). Scale bar=50
µm
Figure 5: Evidence of in vivo tumor-forming ability of glioblastoma spheres. The isolated
glioblastoma spheres were able to form brain tumors in nude mice after intracranial implantations
(a, b), but the non-sphere-forming tumor cells did not, even when implanted cells number reached
50 times of the glioblastoma sphere cells (c) by hematoxylin & eosin staining. The tumors developed
in the mice brain could be stained by human-specific antibodies against NSC markers, nestin (d, e)
and CD133 (g–i). The sections were labeled also with DAPI (blue) to identify nuclei (f, h). The merged
images were also shown (i). Scale bar=1000 µm (a, d); Scale bar=250 µm (b, c, e–i)
Figure 6: Glioblastoma spheres can generate both neurons and glial cells after intracranial
implantations. The tumor mass developed by intracranial implantation of glioblastoma spheres
contained positive stained cells for glial cell marker, GFAP (a–c), oligodendrocyte (d-f), and neuron
marker, β-tubulinIII (g–i). The sections were labeled also with DAPI (blue) to identify nuclei (b, e, h).
The merged images were also shown (c, f, i). Scale bar=250 µm
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